Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors
Authors:
- 21 July 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 41 (10) , 1060-1065
Abstract
Objective: We investigated the role of Ga-68 DOTATATE PET/CT in comparison to F-18 FDG PET/CT in patients with low and intermediate versus high-grade neuroendocrine tumors (NETs). Methods: We identified 81 patients who underwent Ga-68 DOTATATE PET/CT at our institution between May 2017 and December 2018 and met inclusion criteria of biopsy-proven NET with known Ki-67 index, histologic grade, or differentiation. Patients were divided into two groups. Control group included Ki-67 ≤20%, grade 1 or 2, or well-differentiated tumors. Experimental group included Ki-67 >20%, grade 3, or poorly-differentiated tumors. Results: Mean age was 57 years, with 36 males and 45 females. Most common primary sites were small bowel, pancreas, and lung. Most common distant metastatic sites were liver and bone. In the control group (n = 67), median Ki-67 was 4% (range 1–30%). 55/67 (82.1%) DOTATATE and 6/11 (54.5%) FDG scans were positive ( P = 0.04). Positive scans showed >10 lesions in 25/55 (45.5%) DOTATATE and 1/6 (16.7%) FDG scans ( P = 0.18). 40/55 (72.7%) positive DOTATATE and 3/6 (50%) FDG scans showed distant disease ( P = 0.25). In the experimental group (n = 14), median Ki-67 was 68% (range 25–95%). All 14 DOTATATE and all nine FDG scans were positive. Positive scans showed >10 lesions in 4/14 (28.6%) DOTATATE and 5/9 (55.6%) FDG scans ( P = 0.20). 10/14 (71.4%) positive DOTATATE and 7/9 (77.8%) FDG scans showed distant disease ( P = 0.74). Conclusion: All patients with high grade, poorly-differentiated NETs had positive DOTATATE PET/CTs. In these patients, DOTATATE PET/CT did not significantly differ from FDG PET/CT in identifying >10 lesions or distant disease.Keywords
This publication has 19 references indexed in Scilit:
- The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United KingdomJournal of Nuclear Medicine, 2015
- GEP–NETs UPDATE: Radionuclide therapy in neuroendocrine tumorsEuropean Journal of Endocrinology, 2015
- High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term EvaluationJournal of Nuclear Medicine, 2014
- Are G3 ENETS neuroendocrine neoplasms heterogeneous?Endocrine-Related Cancer, 2013
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine TumorsJournal of Nuclear Medicine, 2009
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and SurvivalJournal of Clinical Oncology, 2008
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Expression of Somatostatin Receptor Subtypes 1 to 5 in Tumor Tissue and Intratumoral Vessels in Malignant Endocrine Pancreatic TumorsMedical Oncology, 2003
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic useEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000